Market Pulse
AI
5 events
AI complex whipsaws as Nvidia guidance reignites chip upside while Salesforce re-rates software and Marvell’s muted visibility tests elevated expectations.
Latest Development
Nvidia shares rose about 9%, adding roughly $440B in market cap, after the CFO guided to ~70% fiscal 2028 revenue growth and management said demand exceeds supply amid TSMC and memory constraints.
Salesforce jumped about 22% after Q2 revenue of $11.35B edged estimates and adjusted EPS of $5.90 beat, alongside an expanded Anthropic partnership branded “Claudeforce” to plug Claude into sales workflows.
Marvell reported fiscal Q2 revenue of $2.7B (+37% y/y) and lifted its fiscal 2028 revenue target to about $18B, but shares fell ~8% premarket as the update lacked granular drivers despite strong YTD gains.
A federal judge in San Francisco permanently barred Pentagon actions blacklisting Anthropic as a “supply chain risk,” citing First Amendment and due process issues, while noting a D.C. Circuit case remains pending.
OpenAI rolled out ChatGPT ads in India for free users and a ₹399/month “Go” plan, said ads are live in 38 countries, and plans a self-serve ad platform launch on Sept. 4.
Market reaction
Nvidia rose ~9% with read-through strength cited across AI-linked semis, while Salesforce surged ~22% and IGV was cited up ~5%; Marvell fell about ~8% premarket despite raising its FY2028 target.
Our view
AI exposure stays bid but increasingly selective, with chips supported by Nvidia’s demand> supply framing while software sentiment is leveraged to earnings surprises. Next catalyst is whether peers add credible FY2028 bridges and whether Anthropic’s federal-status uncertainty clears in the D.C. Circuit.
What could change our view
Supply constraints at TSMC or memory ease faster, weakening the demand-gated pricing narrative.
D.C. Circuit keeps Anthropic tagged a supply chain risk, limiting government and contractor usage.
Tickers: $NVDA, $CRM, $MRVL, $AIQ
U.S.-Iran War
3 events
U.S. naval blockade sharply cuts Iran crude exports while Hormuz throughput stays depressed as Tehran floats an Oman corridor tied to U.S. concessions.
Latest Development
Kpler estimates Iran loaded about 260 kbpd for export in August, down over 80% y/y and about 70% vs July, after the U.S. reimposed a naval blockade on July 14.
Reuters cited Iranian officials setting reopening conditions for Hormuz including lifting the U.S. blockade and sanctions plus compensation, alongside an Iran-Oman “designated central channel” proposal with terms still under negotiation.
Bloomberg Law reported DOJ is preparing to revive maritime prize courts to condemn Iran-linked tankers or cargo seized under the blockade, enabling sale proceeds to the U.S. Treasury after a physical seizure and court filing.
Our view
Enforcement-led constraints keep Iranian supply restricted and sustain an elevated crude risk premium until there is a credible, actionable reopening framework for Hormuz. Next to watch is whether corridor talks translate into concrete terms and operational throughput, or whether storage constraints begin forcing production shut-ins.
What could change our view
U.S. concessions unlock corridor and restore Hormuz flows and Iran exports faster.
Seizures and legal escalation or forced shut-ins tighten supply beyond expectations.
Tickers: $CL=F
Macro & Policy Digest
Russia threatens to target UK military assets if British missiles enable deep strikes inside Russia, raising NATO–Russia escalation tail-risk for oil.
Latest Development
Russia’s foreign ministry warned the UK could be deemed legally complicit if Storm Shadow/SCALP are used for deep strikes in Russia and said British installations or equipment in Ukraine or beyond could be targeted.
Our view
We treat the headline as a near-term risk-premium driver rather than a base-path shift, with energy and broad risk pricing most sensitive to further NATO-linked retaliation signals. Watch for confirmation of UK-supplied weapon use in deep strikes and any reported Russian action against assets outside Ukraine as the key escalation trigger.
What could change our view
Verified deep-strike use of Storm Shadow/SCALP prompts cross-border Russian retaliation.
UK or allies adjust support policy, reducing or amplifying escalation pressure.
Tickers: $CL=F
U.S. officials near a Venezuela oil-access pact that could lock in select fields for U.S. developers and guarantee crude supply to America.
Latest Development
Reuters sources say U.S. and Venezuelan officials are discussing a lease-style framework to “lock in” certain Venezuelan oilfields for U.S. company development, with resulting supply guaranteed to the U.S., potentially announced soon.
Our view
Treat this as headline risk for crude until terms are public; any incremental Venezuelan supply impact looks medium-term and execution-dependent rather than immediately price-setting. Key monitor is whether a signed deal clarifies field list, volumes, duration, and sanctions/export licensing compliance mechanics.
What could change our view
Deal is signed with large, near-term volumes and clear sanctions/export permissions.
Negotiations stall or trigger legal/sanctions pushback that blocks operational execution.
Tickers: $CL=F
Sanctions rhetoric on Chinese banks tied to Iran oil flows resurfaces as U.S. and China prepare logistics for Xi’s Washington visit.
Latest Development
Trump said he could sanction Chinese banks linked to converting Iranian oil into funds, after Treasury flagged potential Iran-related secondary sanctions, while U.S. and Chinese officials advanced planning for Xi’s Washington trip.
Our view
A noisy headline cycle that raises China-risk sensitivity without immediate broad market impact until concrete OFAC actions appear. Monitor for any named designations, effective dates, or language signaling systemically relevant Chinese financial institutions are in scope.
What could change our view
OFAC designations or secondary sanctions explicitly naming major Chinese banks.
Xi visit timeline shifts or talks break down, amplifying escalation incentives.
Tickers: $FXI
Reuters poll signals China’s property slump extends into 2027, with deeper investment contraction keeping a growth-risk overhang for China assets.
Latest Development
A Reuters poll (11 institutions, Aug 17–27) sees 2026 home prices -3.4% and 2027 -0.3%, with 2026 property investment -20% and floor-area sales -10%, implying an extended L-shaped adjustment.
Our view
Property remains a multi-year drag, limiting confidence recovery and keeping China equity upside capped absent a clear cyclical turn. Monitor for evidence the downturn is bottoming beyond select top-tier cities and for any policy shift from risk containment toward a faster property-cycle rebound.
What could change our view
Policy pivots to force a rapid property rebound, improving prices and investment.
Property weakness worsens into broader financial or local-government land-revenue stress.
Tickers: $FXI
Company Events
Cybersecurity ripped higher as CrowdStrike and Okta beat and raised guidance, bolstering the AI-driven spend tailwind narrative ahead of Fal.Con.
Latest Development
CrowdStrike jumped ~20% to a record close near $228 on a Q2 beat and raised outlook (revenue $1.47B; ARR $5.84B, +25% YoY; net new ARR $333M), while Okta surged ~29% on its own beat and guide raise.
Market reaction
CRWD rose ~20% to a record close near $228 and OKTA gained ~29%; PANW, ZS, SAIL, and RBRK were cited as up at least ~10% each in sympathy.
Our view
The AI/agent-threat framing reinforces cybersecurity as a demand tailwind, supporting continued outperformance for the complex with CRWD as the key bellwether. Next monitor is next week’s CRWD Fal.Con for incremental signals that sustain the post-earnings momentum.
What could change our view
Fal.Con fails to provide new catalysts, and the post-earnings rally fades.
AI traction remains immaterial with limited metrics, driving multiple compression after sharp moves.
Tickers: $CRWD
Gilead gets FDA approval for Bixlenvo, a once-daily HIV combo aimed at suppressed adults lacking current one-pill options.
Latest Development
The FDA approved Gilead’s Bixlenvo single-tablet regimen combining bictegravir and lenacapavir for adults with suppressed HIV who cannot use existing one-pill regimens; list price is $4,595 per 30-day supply.
Our view
The approval is an incremental positive for Gilead’s HIV franchise, expanding treatment choice without being positioned as a replacement for Biktarvy. Next focus is early real-world uptake in the targeted suppressed segment and how net pricing evolves versus the stated list price.
What could change our view
Adoption underwhelms because the addressable suppressed segment proves smaller than expected.
Net pricing pressure or access frictions reduce the product’s commercial contribution.
Tickers: $GILD
Gap reshuffles Old Navy leadership as Q2 traffic softness hits comps, while an EPS beat drives a sharp after-hours rally.
Latest Development
Gap named Michael Francis Old Navy CEO effective Nov. 2, replacing Haio Barbeito who shifts to an advisor role; Old Navy Q2 sales fell 4% with comps down 4% amid an unanticipated traffic slowdown.
Market reaction
GPS rose about 12% in extended trading after the release, as investors leaned into profit delivery despite softer revenue and Old Navy comp trends.
Our view
The stock’s near-term tone stays supported if investors continue to reward earnings power over top-line softness, with Old Navy execution viewed as a manageable reset under new leadership. Next monitor is evidence that Old Navy traffic and comps stabilize versus consensus expectations in subsequent updates.
What could change our view
Old Navy traffic weakness persists, keeping comps below expectations and pressuring sentiment.
Leadership transition signals operational disruption rather than a planned handoff.
Tickers: $GPS
RSP tops $100B as equal-weight S&P 500 leads cap-weight in 2026 YTD, signaling continued investor push toward broader equity breadth.
Latest Development
Invesco’s RSP surpassed $100B AUM in August after about $1.5B net inflows in July; as of Aug. 27 it was up 15.76% YTD versus 12.13% for the S&P 500.
Our view
Equal-weight should stay bid versus cap-weight as investors keep rotating toward broader participation and systematic rebalancing trims concentrated winners. Watch relative RSP/SPY trend and breadth across industrials and financials; a renewed narrow mega-cap surge would likely stall the trade.
What could change our view
Mega-cap-led rally reasserts itself, reversing breadth and equal-weight outperformance.
Material flow reversal from RSP back into cap-weight S&P 500 funds.
Tickers: $RSP
Go deeper -
For intraday developments, follow our Midday posts.
For the close, the wrap, and next-day trade ideas, read the Evening Memo.
For deeper work, Forward Valuation covers multi-week single-name setups (paid subscribers only).
Deep Dive is where we publish our full thematic research for paid subscribers.
Informational only; not investment advice. Sources deemed reliable.